Semaglutide

A recent study in JAMA Ophthalmology links semaglutide medications, used for weight loss and diabetes, to an increased risk of NAION, a rare eye condition causing sudden vision loss.

Research showed promising results for semaglutide (Wegovy) in reducing heart risks for obese patients already battling cardiovascular diseases.

Despite whether or not patients experience weight loss, a well-known anti-obesity medication has been proven to reinstate the functionality of immune cells that fight cancer.

A recent study in JAMA Ophthalmology links semaglutide medications, used for weight loss and diabetes, to an increased risk of NAION, a rare eye condition causing sudden vision loss.

Research showed promising results for semaglutide (Wegovy) in reducing heart risks for obese patients already battling cardiovascular diseases.

Despite whether or not patients experience weight loss, a well-known anti-obesity medication has been proven to reinstate the functionality of immune cells that fight cancer.